ABSTRACT
FBXO22 encodes an F-box protein which acts as a substrate-recognition component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex. Despite its known roles in the post-translational ubiquitination and degradation of specific substrates, including histone demethylases, the impact of FBXO22 on human development remains unknown. Here, we characterize a pleiotropic syndrome with prominent prenatal onset growth restriction and notable neurodevelopmental delay across 14 cases from 12 families. Through exome and genome sequencing, we identify three distinct homozygous loss-of-function FBXO22 variants segregating with the disease: p.(Arg53Serfs*13), p.(Pro3Leufs*3) and p.(Val240Alafs*6), all predicted to lead to premature translation termination due to frameshift effects. We confirm that patient-derived primary fibroblasts are bereft of FBXO22 and show increased levels of the known substrate histone H3K9 demethylase KDM4B. Accordingly, we delineate a unique epigenetic signature for this disease in peripheral blood. Altogether, we identify and demonstrate that FBXO22 deficiency leads to a pleiotropic syndrome in humans encompassing growth restriction and neurodevelopmental delay, the pathogenesis of which may be explained by broad chromatin alterations.
Competing Interest Statement
P.B., S.K., N.O., M.F., J.P.B. and A.M.B.-A. are employees of Centogene GmbH. All other authors declare no conflicts of interest.
Funding Statement
N.B.R. is a recipient of Singapore Ministry of Health RIE2025 National Medical Research Council OF-YIRG award (OFYIRG23jan-0036, MOH-001341) administered by the Agency for Science, Technology and Research. A.A.M is a recipient of Sultan Qaboos University Strategic research funding (SR/MED/GENT/16/01). B.R. is a fellow of the Branco Weiss Foundation (Switzerland) and an EMBO Young Investigator (Europe) and is funded by BESE at KAUST in the KSA. We would also like to acknowledge the support of the Mohammed Bin Rashid University of Medicine and Health Sciences and Al Jalila Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved and ethical approval for this work was given by the Agency of Science, Technology and Research (A*STAR) IRB (2019-087) in Singapore and at King Abdullah University of Science and Technology (KAUST) IRB (23IBEC090) in the KSA.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data and code parameters that support the findings of this study are detailed within the methods and supplemental information, or from the corresponding authors upon request.